Hodgkin's disease+2
Not recruitingStudy on the Safety of HSP-CAR30 Immunotherapy for Patients with Relapsed or Refractory CD30+ Hodgkin and Non-Hodgkin Lymphoma
Study on the Safety of HSP-CAR30 Immunotherapy for Patients with Relapsed or Refractory CD30+ Hodgkin and Non-Hodgkin Lymphoma
- Disease:Hodgkin's diseaseNon-Hodgkin's lymphoma+1
- Substances:HSP-CAR30Tocilizumab+3
Spain- Participants:18–64 years · 65+ years
- Substances:HSP-CAR30
- Sponsor:Fundacio Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau








